Hims & Hers Health, Inc.
NYSE:HIMSMedical - Equipment & Services
+$1.11 today
- Market cap
- $3.85B
- Beta
- 2.40
- P/E (TTM)
- -569.3
- EPS (TTM)
- -$0.06
Volume 9.53M
Average 26.18M
HIMS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Hims & Hers Health, Inc.NYSE: HIMS
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q3 FY2026 depreciation & amortization of $38.21M rose 116.3% year over year, behind the +153.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 29.6% from the prior quarter. Over 3 fiscal years it compounded at +93.9% a year.
Context
- Depreciation & amortization amounted to 2.3% of revenue in FY2025, up 1.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +116.3% toward the trailing-twelve-month pace of +153.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 54.5M USD
- Year-over-year change
- +218.9%
- 4-year CAGR
- +91.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.5M | +218.9% |
| FY2024 | 2024-12-31 | 17.09M | +79.6% |
| FY2023 | 2023-12-31 | 9.52M | +27.3% |
| FY2022 | 2022-12-31 | 7.47M | +83.4% |
| FY2021 | 2021-12-31 | 4.08M | — |
Depreciation & Amortization vs competitors
How HIMS compares with its peers on the latest reported figures
- HIMS's LTM Sep 2026 depreciation & amortization of $107.73M is the 5th largest of the 10 companies compared; the peer median is $92.27M.
- Its year-over-year change of +153.7% is the highest of 9, against a peer median of -0.5%.
- Depreciation & amortization amounts to 3.8% of revenue for HIMS, versus a peer median of 4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $787M | -4.1% | +2.3% | 5.1% | |
| LTM Sep 2026 | $569M | +0.0% | -4.7% | 3.7% | |
| LTM Sep 2026 | $474.6M | +15.7% | +4.2% | 8.2% | |
| LTM Jun 2026 | $403.5M | +22.7% | -0.1% | 9.7% | |
| LTM Sep 2026 | $107.73M | +153.7% | +93.9% | 3.8% | |
| LTM Jun 2026 | $92.27M | +99.8% | +65.2% | 5.2% | |
| LTM Mar 2026 | $85.7M | -1.0% | -0.4% | 4.1% | |
| LTM Dec 2025 | $53.3M | — | +6.1% | — | |
| LTM Mar 2026 | $9.51M | -12.9% | +2.3% | 2.7% | |
| LTM Mar 2026 | $2.76M | -127.4% | -55.7% | 1.3% | |
| Peer median (excluding HIMS) | $92.27M | -0.5% | +2.3% | 4.6% | |
Competitors are the stored peer set for HIMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (107.66M) | (65.68M) | (23.55M) | 126.04M | 128.37M |
| Depreciation & Amortization | 4.08M | 7.47M | 9.52M | 17.09M | 54.5M |
| Deferred Income Tax | (3.39M) | (594K) | (13K) | (61.65M) | (12.96M) |
| Stock-Based Compensation | 67.21M | 42.82M | 66.08M | 92.32M | 135.24M |
| Change in Working Capital | 3.46M | (14.2M) | 20.82M | 78.62M | (29.16M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | (9.63M) | (8M) | (902K) | (41.61M) | (13.72M) |
| Accounts Payables | 9.85M | 12.72M | 7.32M | 43.71M | 30.3M |
| Other Working Capital | 3.23M | (18.91M) | 14.4M | 76.53M | (45.74M) |
| Other Non-Cash Items | 1.89M | 3.65M | 626K | (1.34M) | 24.02M |
| Operating Cash Flow | (34.41M) | (26.53M) | 73.48M | 251.08M | 300.01M |
| Capital Expenditures | (5.01M) | (7.25M) | (26.49M) | (52.75M) | (226.05M) |
| Acquisitions (Net) | (46.47M) | (459K) | 0 | (15.4M) | (145.23M) |
| Purchases of Investments | (266.63M) | (187.7M) | (157.24M) | (160.56M) | (745.84M) |
| Sales of Investments | 161.84M | 230.11M | 171.63M | 209.67M | 108.7M |
| Other Investing Activities | (4.18M) | (4.53M) | (9.27M) | (11.1M) | (16.55M) |
| Investing Cash Flow | (156.27M) | 34.7M | (12.11M) | (19.05M) | (1.02B) |
| Debt Repayment | 1.19M | 0 | 0 | 0 | 918.78M |
| Common Stock Issued | 272.69M | 0 | 0 | 0 | 17.47M |
| Common Stock Repurchased | (22.03M) | 0 | (2M) | (83.04M) | (89.96M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (16.81M) | (33.13M) | (9.48M) | (24.81M) | (116.67M) |
| Financing Cash Flow | 235.04M | (33.13M) | (11.48M) | (107.85M) | 729.62M |
| Effect of Forex Changes | (73K) | (53K) | (11K) | (270K) | 3.36M |
| Net Change in Cash | 44.29M | (25.01M) | 49.89M | 123.92M | 8.03M |
| Free Cash Flow | (39.42M) | (33.78M) | 46.99M | 198.33M | 73.96M |
Hims & Hers Health, Inc.
NYSE:HIMS
Intrinsic Alpha fair value
Locked
Current Price
$17.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.